Given the potential for ATRis to serve as a salvage strategy for patients progressing on PARP inhibitors, particularly in the ARID1A-deficient or HR-proficient gastric cancer subgroups, integrating ARID1A testing, via IHC or genomic profiling, into clinical workflows may enhance therapeutic precision. Here, PARP1 is linked to gastric cancer.